Louisiana State Employees Retirement System Sells 200 Shares of Haemonetics Co. (NYSE:HAE)

Louisiana State Employees Retirement System cut its holdings in Haemonetics Co. (NYSE:HAE) by 1.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 14,200 shares of the medical instruments supplier’s stock after selling 200 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Haemonetics were worth $1,141,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of HAE. Thrivent Financial for Lutherans raised its position in Haemonetics by 6,573.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier’s stock valued at $70,267,000 after buying an additional 836,623 shares during the last quarter. Silvercrest Asset Management Group LLC acquired a new stake in shares of Haemonetics in the first quarter valued at approximately $38,706,000. Mizuho Markets Americas LLC bought a new stake in shares of Haemonetics in the second quarter worth $30,080,000. Allspring Global Investments Holdings LLC lifted its position in shares of Haemonetics by 75.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier’s stock worth $63,933,000 after purchasing an additional 343,214 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Haemonetics by 327.0% during the second quarter. The Manufacturers Life Insurance Company now owns 307,564 shares of the medical instruments supplier’s stock worth $25,445,000 after purchasing an additional 235,535 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Price Performance

HAE stock opened at $71.48 on Friday. The company’s 50-day moving average price is $75.46 and its two-hundred day moving average price is $82.76. The firm has a market cap of $3.66 billion, a P/E ratio of 32.05, a P/E/G ratio of 1.11 and a beta of 0.32. The company has a quick ratio of 2.33, a current ratio of 3.76 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 12 month low of $70.25 and a 12 month high of $97.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The firm had revenue of $336.17 million for the quarter, compared to analyst estimates of $335.08 million. During the same quarter in the prior year, the firm earned $1.05 earnings per share. The firm’s revenue for the quarter was up 8.0% on a year-over-year basis. On average, analysts anticipate that Haemonetics Co. will post 4.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on HAE. JMP Securities restated a “market outperform” rating and issued a $125.00 price objective on shares of Haemonetics in a report on Tuesday, August 13th. Citigroup decreased their price target on Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd. Barrington Research reiterated an “outperform” rating and set a $108.00 price objective on shares of Haemonetics in a research note on Monday, September 23rd. BTIG Research started coverage on shares of Haemonetics in a research note on Tuesday, September 10th. They issued a “buy” rating and a $112.00 target price for the company. Finally, Bank of America assumed coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price target on the stock. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $106.14.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.